MedTrace Logo

Biological Treatment of Amyotrophic Lateral Sclerosis

NCT02193893 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-07-18

No results posted yet for this study

Summary

The purpose of this study is to test the safety and effectiveness of an autologous bone marrow-derived stem/progenitor cells infusion in the subjects with diagnosed amyotrophic lateral sclerosis.

Conditions

Interventions

OTHER

Biological: Cell-based therapeutics

Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.

OTHER

Symptomatic treatment of ALS

Symptomatic neurological treatment of ALS

Sponsors & Collaborators

  • Pomeranian Medical University Szczecin

    lead OTHER

Principal Investigators

  • Boguslaw Machalinski, MD, PhD · Pomeranian Medical University Szczecin

  • Przemyslaw Nowacki, MD, PhD · Pomeranian Medical University Szczecin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2017-07-31
Completion
2017-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193893 on ClinicalTrials.gov